Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab

Expert Review of Hematology

Volumn 4, Issue 1, 2011, Pages 9-16

  Vallejo, Carlos ^a   Ríos, Eduardo ^b   De La Serna, Javier ^c   Jarque, Isidro ^d   Ferrá, Christelle ^e   Sánchez Godoy, Pedro ^f   Solano, Carlos ^g   De La Cámara, Rafael ^h   Rosell, Ana Isabel ⁱ   Varela, Rosario ^j   García, María Dolores ^k   González Barca, Eva ^l   López, Javier ^m   Pérez, Elena ⁿ   Ferrer, Secundino ^o   Casado, Luis Felipe ^p   Vázquez, Lourdes ^q   Villalón, Lucía ^r   García Marco, José A ^s  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL SEVERO OCHOA   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁱ HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^j HOSPITAL JUAN CANALEJO   (Spain)

^k Laboratory of Hematology   (Spain)

^l CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^m HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁿ HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^o HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^p HOSPITAL VIRGEN DE LA SALUD   (Spain)

^q HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^r HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^s HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

more..

Author keywords

alemtuzumab; antiviral therapy; chronic lymphocytic leukemia; cytomegalovirus disease; cytomegalovirus infection; lymphoproliferative diseases

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FAMCICLOVIR; FLUDARABINE; MITOXANTRONE; PENTOSTATIN; RITUXIMAB; STEROID; VALACICLOVIR; VALGANCICLOVIR; VINCRISTINE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; B CELL LEUKEMIA; CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; HOSPITAL; HUMAN; INCIDENCE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SEZARY SYNDROME; T CELL LEUKEMIA; TREATMENT DURATION; VIREMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEROIDS;

EID: 79951786213     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.77     Document Type: Article

References (32)

1. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr. Opin. Oncol. 12, 574-581 (2000). (Pubitemid 32039657)
2. Ravandi F, OBrien S. Alemtuzumab. Expert Rev. Anticancer Ther. 5, 39-51 (2005). (Pubitemid 40287435)
3. Dearden CE. Alemtuzumab in lymphoproliferative disorders. Rev. Clin. Exp. Hematol. 6, 435-448 (2002). (Pubitemid 36648066)
4. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br. J. Haematol. 114, 891-898 (2001). (Pubitemid 32953751)
5. Osterborg A, Foã R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23, 1980-1988 (2009).
6. Christian BA, Lin TS. Antibody therapy for CLL. Semin. Hematol. 45, 95-103 (2008).
7. Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100, 768-773 (2002). (Pubitemid 34832599)
8. Hillmen P, Skotnicki A, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25, 5616-5623 (2007).
9. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol. 15, 1567-1574 (1997). (Pubitemid 27167394)
10. Rai KR, Coutre S, Rizzieri D, et al. Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis. Blood 98, 365a (2001).
11. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99, 3554-3561 (2002). (Pubitemid 34534522)
12. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol. 23, 2971-2979 (2005). (Pubitemid 46224116)
13. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103, 3278-3281 (2004). (Pubitemid 38525651)
14. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med. 347, 452-453 (2002). (Pubitemid 34851846)
15. Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin. Lymphoma 3, 105-110 (2002). (Pubitemid 35277016)
16. Laurenti L, Piccioni P, Cattani P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 89, 1248-1252 (2004). (Pubitemid 39390451)
17. OBrien S, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin. Lymphoma Myeloma 7, 125-130 (2006). (Pubitemid 44596594)
18. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J. Clin. Oncol. 24, 2337-2342 (2006). (Pubitemid 46630666)
19. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 46, 219-234 (1975).
20. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48, 198-206 (1981). (Pubitemid 11064396)
21. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin. Infect. Dis. 34, 1094-1097 (2002). (Pubitemid 34289682)
22. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87, 4990-4997 (1996). (Pubitemid 26189840)
23. Worth LJ, Thursky KA. Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention. Leuk. Lymphoma. 47, 2435-2436 (2006). (Pubitemid 44932633)
24. Ng AP, Worth L, Chen L, et al. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica 90, 1672-1679 (2005). (Pubitemid 41814993)
25. Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br. J. Haematol. 132, 3-12 (2006). (Pubitemid 43381565)
26. Lamba R, Carrum G, Myers GD, et al. Cytomegalovirus (CMV) infection and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogenic stem cell transplantation with alemtuzumab. Bone Marrow Transpl. 36, 797-802 (2005). (Pubitemid 41613303)
27. OBrien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumaβ-therapy. Blood 111, 1816-1819 (2008). (Pubitemid 351451487)
28. Hwang YY, Cheung WWW, Leung AYH, Tse E, Au WY, Kwong YL. Valganciclovir thrice weekly for prophylaxis against cytomegalovirus reactivation during alemtuzumab therapy. Leukemia 23, 800-801 (2009).
29. Han XY. Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer. J. Clin. Microbiol. 45, 1126-1132 (2007). (Pubitemid 46626474)
30. Smolej L. Valganciclovir versus valaciclovir for prevention of alemtuzumaβ-induced cytomegalovirus reactivation: what are the implications for routine clinical practice? Blood 112, 2167 (2008).
31. Osterborg A, Foã R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23, 1980-1988 (2009).
32. Cheung WW, Tse E, Leung AYH, Yuen KY, Kwong YL. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab. Am. J. Hematol. 82, 108-111 (2007). (Pubitemid 46155272)